saw to non-incisional in months momentum Thanks, rollout U.S. interest as Jim. COVID-XX, a of glaucoma the couple Prior of therapy. XXXX of first probe our encouraging laser the physicians MPX onset very MicroPulse our the we of and expanded of the revised
in year's earnings As in interest early meeting. March, meeting we our noted versus call last Glaucoma at the QX American doubled Society
reengaging on Previously, probe and mid-year. embodied reaching the the attracted the to way our of our the dormant improvements sites we with were goal and we're in surpassed had customers in us of by U.S. to well revised XX% conversion completion
without Therefore, to be that before COVID-driven slow cure could of patients' It's treatment because glaucoma important to the and increasingly incremental permanent a occur to in the vision. need approaches whose of requires keep disease acceptable rate paradigm to is timeframe a progression. a restrictions still progressive of damage procedures invasive performed sequence glaucoma within mind deferred disease an
that the IOP visit. glaucoma patients effectively extends more surgeries in despite volume remains The therapy interest non-incisional lowers patient the our on current and complex need procedure before incision-based runway intact limits and
remaining growth in we Given intermediate confident are potential longer-term our this very and dynamic, promising.
mandated Late and or all in QX, implemented most began the non-COVID visits ophthalmology procedures closing orders, hospitals, such staffing to societies and to for recommendations to defer to governments offices as by and and stop to of measures patients shelter-in-place patient urgent COVID-XX for be minimal the only avoid activity non-urgent reduced furloughed medical recommendations spread procedures.
and significant experiencing decisions customers also April. the limitations made physician equipment short-term that capital they March procedures our of in through resulted second in to defer purchases half to persisted conducting This
were GX treating approximately during and in the In this to remainder accounts outreach our existing solely period, cases. fact emergency were XX% closed
our adjustments impact COVID-XX and mitigate risk remain steps in to to business taken made to close drive customers also visiting our in of momentum our customers selectively year. this order meetings the to with our and the methods has digital for and who the forward needed to We accessible to continue contact and were virtual employing IRIDEX we limit customer's, beginning more employees. achieved of operations business in
the in to their to mid-March A located We health determine continues recommendations recommended our in-office instituted safety. we transitioned measures small functions. Bay follow in continue almost quickly San and remote support appropriate to national followed all IRIDEX local guidelines social are ensure number environment. a from agencies, We'll such employees of and to government as at essential after time team our county operations facilities distancing resume the other the and work to care Francisco and to Area
has Our customers. activity largely engagement continue to strong able with sales to sales organization encouragingly and has virtual shifted been
replacement global attended program, as continuity widely a have maintained to number sales accounts broad as not virtual a closely and shifted While and effectively possible. for clinical training, conferences, face-to-face industry a meetings on-site with of we hosting events key
one-time the with and we We've virtual physicians us. dozen in clinic grand than many schedules these when over clinical eight and of surgical more in XX more conducted clinical staff available closures typically to is physicians their that at were training engage surgicenter with to One rounds engage opportunity could a engaging are and full. sessions,
widespread half, today quarter, As there the see was the second of treatment. that we quarter. two we staged shutdown; first the was intraocular we our In phases choice second see the to reopening. therapy of transscleral were in and only the needed In environment, pressure speak performed within near patients midpoint half the desirable high for urgently with laser expect procedures shutdown in activity a urgent
for conducted that to reduction hundreds We we required a the procedures, registrants, exposure treatment short of discussing XXX as a selecting XXX only risk and and tool procedures solution. attendees and follow-on the minimized Customers those role viewings are minimum patient us because follow-up. was for demonstrated over solution a April, IOP therapy non-incisional procedure especially they position time that in attracted exploring IRIDEX that of us Early urgent the choices in were important webinar and interest telling environment. our effective
expect before of rest plan also now. But phase quarter. ophthalmologists of in The time they to nearly for second patient and to operating to show telling us many surgery indicated are to XX% June. a reopen extended safe our of under management And and starting Surveys the anticipated rescheduling XX% to customers cases patient survey centers allow end recent plan in initially capacity reopen half to of be the in equipment cleaning. May is reduced reopening
XX% capacity of estimating grown to over and XX% are initially couple months. at Some a
procedure our of environment, In are minimal encouraged and our customers we're saying simplicity this hear valued. patient to follow-up the highly
So, COVID increased non-incisional patients, been along these to drive attractiveness promoting value of in while adoption the elements environment. progressing importance this glaucoma all we've for has extended runway and
customers engaged and seminars by proctoring web-based are the for ready to customers. supporting support prospective customers our in conducting physician and new remote We certification educational and cases, environment
U.S. in XX conducted with For multi-doctor we've large than teaching several top-tier the groups example, including at trainings institutions. physician more participation, major virtual often
engagement our by encouraged methods. these the are We through and customers achievable with progress that's
sales glaucoma primarily world. premier international the through Our in distributors are around
COVID Our was the us. attendees, but to of XXX the online worldwide be a internationally, restricted which had our In MPX over roll for training conducted April, a world. meeting for with distributors were record we virtual adjusted plans probe version revised out in to
detailed Again, strong. We we're potential followed that and the distributors, with very individual training indicating and direct engagement and virtual staff focus with longer-term remains leaders with intermediate that encouraged country. in opinion up key the country
and are market and we're restrictions plan are in to many the states monitoring getting return the restrictions use the determine elective encouraged In are field by strong actual such reports news easing presence updates term. state-by-state that and of the our near team from U.S., surgeries to in or our
stage, with capacity starting, In pace regions Latin uncertain many Union of or type this is various other outside Pacific procedures markets. progressing but variables regions volumes, and Asia and limited is the recovery opening; leading; which of procedure simply showing at to and in evolving. which are at recovery be quantitatively procedure still U.S., prioritized are still European there predict too rates the will Therefore, America
our reasons glaucoma, and volumes. U.S. believe worldwide to and all positioned regions grow for visits the various we Summarizing expand patient as and to the recover begin discussed, well is of IRIDEX procedure volume I've
where effective, our it's to forward support Our team customers is to eager move continue and do appropriate safe and durable, glaucoma the expanding procedures. role to non-incisional so, for
Turning business. to our retina
of retinal price-sensitive. in position platform of a broad a leadership Our that however, and comprehensive continues remains diseases, medical to and competitive the hold surgical range treatment market
of but also are appetite economic revenue, from yet in Customers impacts capital we for their deferral so shift experiencing quantify purchases. can't expect procedure the significant
Some of we at are periods quarter. at and clear, that shutdown the centers, the deferrals experienced first and because offices of surgery the end
to How still recovers volume purchase longer-term is what laser system degree and and uncertain. short-term
However, tends a and failing it's in important to sales be mature segment, of is surgical old laser to note systems, retina portion that equipment and of like significant or our replacement resilient. more a
to recovery the that overall business economic expect the reflect We of practices.
segment our ophthalmic additional probes. disposable surgeries our of to for That glaucoma a similar recovery An discussed business important is surgical retina is likely as for EndoProbes. we've follow
and for In and glaucoma combination overall volume of the XXXX, in recovery. to about sales our well probes EndoProbes up recovery drive half revenue, procedures retina both made we're positioned
support What control promote makes which team our forecasting progresses to However, is benefits to the so committed. deliver we much efforts recovery variability is and in difficult. our how we fully
our With systems March manufacturing in experienced transmission we reported China, development product to development government and acted COVID-XX. the of Wuhan, laser that for shutdowns delays projects, new and restrict as regards Chinese you to had our in to partner project
the became to IRIDEX began subject They time online to mid-March and remotely. in orders work came back about shelter-in-place
launches and working we product to goal good later closely a toward effectively making progress However, this are year. achieve
we March, efficiencies projected to demand chain business reported support period. that remain we this supply have we operational during a As the meet and and to confident resources capital our stable in
our we glaucoma COVID-XX as initiatives believe will works We for drive return outbreak world to will demand eventually through normalcy therapy. our accelerate the and the
non-incisional pressure optimistic We have intraocular in the newfound and of we lowering the community of follow-up. minimal our for enhanced glaucoma recognition effective requires role durable are that patient
the share the moderate to millions We for continue severe glaucoma patients our of increasing of for see the opportunity significantly worldwide. treatment to
to for With call questions. turn I'd to Operator? the over the that, like operator
